Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1997-11-18
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514912, A61K 3700
Patent
active
056887655
ABSTRACT:
The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutic amount of an androgen or androgen analogue or a therapeutic amount of TGF-.beta. is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sjogren's syndrome. Measurement of the increased tear levels of TGF-.beta. is disclosed as a diagnostic test to monitor the therapeutic effect of topical treatment with androgen or androgen analogues.
REFERENCES:
Sato et al., "Impact of Androgen Therapy in Sjogren's Syndrome: Hormonal Influence on Lymphocyte Populations and la Expression in Lacrimal Glands of MRL/Mp-Ipr/Irp Mice," Invest. Opht. & Vis. Science 33:2537-2545 (1992).
Sato et al., "Comparative Influence of Steroid Hormones and Immunosuppressive Agents on Autoimmune Expression in Lacrimal Glands of a Female Mouse Model of Sjogren's Syndrome," Inves. Opht. & Vis. Sci. 35:2632-2642 (1994).
Rocha et al., "Effect of Androgen Analogue Treatment and Androgen Withdrawal on Lacrimal Gland Inflammation in a Mouse Model (MRL/Mp-Ipr/Ipr) of Sjogren's Syndrome," Regional Immunology 6:1-8 (1995).
Sullivan et al., "Influence of Steroids and Immunosuppressive Compounds on Tear IgA Levels in a Mouse Model of Sjogren's Syndrome," Invest. Opht. & Vis. Science, p. 845.
Sullivan et al., "Potential Therapeutic Approach for the Hormonal Treatment of Lacrimal Gland Dysfunction in Sjogren's Syndrome," Clin. Immunol. and Immunopath. 64:9-16 (1992).
Ono et al., "Analysis of Androgen Receptors and Cytokines in Lacrimal Glands of Mouse Model of Sjogrens' Syndrome," Invest. Opht. & Vis. Science 35:1793 (1994).
Clark et al., "Mechanisms of Action of Steroid Hormones," pp. 35-90.
Mountz et al., "Murine models for systemic lupus erythematosus and Sjogren's Syndrome," Current Science ISSN pp. 738-756 (1991).
Sibbitt, "Ongogenes, Growth Factors, and Autoimmune Diseases," Anticancer Research 11:97-114 (1991).
Firestein, "Cytokines in Autoimmune Diseases," Concepts Immunopathol. 8:129-160 (1992).
Kroemer et al., "Cytokines and Autoimmune Disease," Clin. Immunol. & Immunopath. 61:275-295 (1991).
Dinarello, "Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases," seminars in Immunology 4:133-145 (1992).
Mountz et al., "Murine models of autoimmune disease," Current Science ISSN pp. 621-629 (1992).
Wahl, "Transforming Growth Factor .beta.: The Good, the Bad, and the Ugly," Journ. of Exp. Med. 180:1587-1590 (1994).
Wakefield et al., "The Role of cytokines in the Pathogenesis of Inflammatory Eye Disease," Cytokine 4:1-5 (1992).
Rosenbaum, "Cytokines: The Good, The Bad, and The Unknown," Invest. Ophth. & Vis. Science 34:2389-2391 (1993).
Fox et al., "Pathogenesis of Sjogren's Syndrome," Rheumatic Disease Clinics of North America 18:517-539 (1992).
Fay Zohreh
The Schepens Eye Research Institute, Inc.
LandOfFree
Ocular therapy in Sjogren's syndrome using topically applied and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular therapy in Sjogren's syndrome using topically applied and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular therapy in Sjogren's syndrome using topically applied and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1565625